🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Atorvastatin injection

    CUMBERLAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  2. Atropine Sulfate 0.025% Eye Drops, solution in single-dose container, Atropine Sulfate 0.005% Eye Drops, solution in single-dose container, Placebo Atropine Sulfate Eye Drops, solution in single-dose container, Atropine Sulfate 0.01% Eye Drops, solution in single-dose container, Atropine Sulfate 0.05% Eye Drops, solution in single-dose container

    Lacuna Pharma Pty Ltd

    Myopia progression in children

    phase 2 small molecule active

    1 trial

  3. Atuliflapon, SALBUTAMOL, Placebo to Atuliflapon

    AstraZeneca AB

    Moderate-to-Severe Uncontrolled Asthma

    phase 2 small molecule active

    1 trial

  4. Autologous bone marrow mononuclear cell transplantation

    EuroGen Pharmaceuticals Ltd

    Spinal Cord Injury

    phase 2 mab terminated

    1 trial

  5. Avapritinib, Avapritinib, Avapritinib Placebo Tablets

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis (ISM)

    phase 2 small molecule active

    1 trial

  6. Axatilimab

    Syndax Pharmaceuticals

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Axatilimab

    Syndax Pharmaceuticals

    Chronic Graft-versus-host-disease

    phase 2 small molecule active

    2 trials

  8. Axitinib

    ADIAL PHARMACEUTICALS, INC.

    Melanoma

    phase 2 small molecule completed

    1 trial

  9. Azacitidine

    Syndax Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. Azenosertib

    Zentalis Pharmaceuticals

    Uterine Serous Carcinoma

    phase 2 small molecule active

    2 trials

  11. Azenosertib

    Zentalis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  12. Azenosertib

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  13. BAY 3283142, BAY 3283142 PLACEBO, BAY 3283142, BAY 3283142

    Bayer AG

    Chronic kidney disease

    phase 2 small molecule active

    1 trial

  14. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  15. BFB759, Placebo

    Blue Earth Diagnostics Ireland Ltd

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  16. BGG492

    Novartis Pharmaceuticals

    Adrenocortical Adenoma

    phase 2 small molecule completed

    1 trial

  17. BGJ398

    Novartis Pharmaceuticals

    Recurrent Glioblastoma or Other Glioma Subtypes

    phase 2 small molecule completed

    1 trial

  18. BHV-7000, BHV-7000, Placebo for BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  19. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  20. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  21. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  22. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  23. BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

  24. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources